Stephen Johnston is Professor of Breast Cancer Medicine and Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre for Cancer at the Royal Marsden. He graduated in 1983 from Trinity College at The University of Cambridge, and in 1986 from The Medical School at The University of Newcastle upon Tyne. He trained in General Medicine at St Bartholomew's Hospital and Hammersmith Hospital in London, and subsequently in Medical Oncology at the Royal Marsden Hospital. He gained his PhD from the Institute of Cancer Research at the University of London, and took up his current position as Medical Oncologist on the Breast Unit at the Royal Marsden Hospital in 1997. He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase II / III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors. He has published over 230 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national & international meetings. He is a member of several scientific committees and advisory boards, a Faculty Member at the American Society for Clinical Oncology, the Deputy-Editor of the international journal ‘Breast Cancer Research’, and a former Trustee of the UK charity ‘Breast Cancer Campaign’ having also been Chairman of their Scientific Advisory Board.
Professor Peter Schmid was appointed as Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London, in 2013. He is Clinical Director of Breast Cancer at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. Professor Schmid is also Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre. He leads the academic breast cancer programme and the cancer immune therapy group at Barts Cancer Institute.
Professor Schmid trained in medicine at Ludwig-Maximilians-University Munich, Technical University of Munich and University of Aberdeen. He was awarded scholarships by the 'Studienstiftung des deutschen Volkes', the 'Hanns-Seidel-Foundation', and the 'Deutscher Akademischer Austauschdienst'. Professor Schmid completed a MD on mitochondrial creatine kinase at the Technical University Munich. He subsequently trained at the University Hospital Charité in Berlin in internal medicine, haematology and oncology, where he became head of breast cancer research and the phase I programme. He completed his PhD at the Charité University in Berlin in 2005 and was awarded the "habilitation and venia legendi" and an external readership by the Charité University in 2006. From 2005-2010, Prof. Schmid was a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. In 2010, he was appointed as Foundation Chair in Cancer Medicine at the University of Sussex, and he was Director of the Clinical Investigation and Research Unit at Brighton and Sussex University Hospitals until his move to Barts.
Professor Schmid’s specialist cancer interests are breast cancer, cancer immune therapy and early drug development. His research interests lie in stratified cancer medicine utilising novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. Professor Schmid has successfully led more than 20 national/international academic clinical studies, ranging from phase I to III, and several translational research programmes. He leads a collaborative group to establish circulating tumour DNA as a biomarker and is principal investigator of 2 ongoing, prospective international biomarker studies on predictive epigenetics from circulating tumour DNA.
Professor Schmid is a member of several national and international cancer organizations and research groups and has been involved in international consensus meetings on the management of breast cancer. Professor Schmid is a member of ESMO breast cancer Faculty, the UK NCRN breast cancer study group and of the breast cancer and translational research steering groups of the German cooperative group of medical oncology. He has authored or –co-authored 165 publications and has published a book on the management of bone metastases (3rd edition).
Ass. Pr. MOHAMMAD AL FALASI
University of United Arab Emirates
Chair of the Otolaryngology -Head and Neck Surgery Department at Tawam Hospital SEHA
Vice President of the Emirates ENT Society
Member of the American Rhinology Society
Member of the Arab Rhinology Society
Member of the European Rhinology Society
Member of the American Head and Neck Society
Member of the European Otolaryngology Society
Post Fellow in Head and Neck Oncology and Micro-vascular Flaps
Post Fellow in Rhinology and Base of Skull Surgery
University of Montreal, Canada
Published a number of articles in head and neck and sinus disease
Presented in international Conferences.
Special interest and expertise:
Rhinosinusitis, Endoscopic management of Sinonasal Tumors and Anterior Base of Skull Tumors, Pituitary Tumors, Thyroid Surgery, Parathyroid Surgery, Salivary Gland Surgery, Oral Cancers, Oropharynx Cancers, Pharynx Cancers, Laryngeal Cancers and Head and Neck Reconstruction.
Hamdy A. Azim is a Professor of Clinical Oncology at Cairo University in Egypt. He finished his doctorate degree on the management of non-Hodgkin's lymphoma in adults (1986). Dr Azim then obtained postdoctoral training at the Medical Oncology Department in NCI- Milan ( 1987) , the Medical Oncology Department in Curie Institute -Paris, France ( 1988-1989) , and at the Department of Adult Lymphoma and Bone Marrow Transplants, St. Louis Hospital in Paris( 1996) Dr Azim is a member of numerous societies including ASCO, ASH, ESMO , the European Blood and Marrow Transplantation Society (EBMT), and the American Society of Therapeutic Radiology (ASTRO). He sits on several international scientific / steering committees and has been invited as a speaker in more than 300 regional and international conferences. He also served as a speaker for the ASCO online educational programme. His main interests lie in breast cancer, molecular target therapies , bone metastases , Lymphoma and translation research where he has published more than 70 papers and 400 abstracts. Dr. Azim has been a principle investigator of many Multicenter international clinical trials mainly in breast cancer Dr Azim is an editor for the Journal of Clinical Lymphoma, The Lancet (Middle East edition), and the Journal of Clinical Oncology and Nuclear Medicine Cairo university. He was the chief editor of 2 educational books ( ASCO – PANARAB Lymphoma , 1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006). Dr Azim serves as a referee for the Annals of Oncology Journal, THE BREAST , Chemotherapy Journal , Advances in Cancer Research and Journal of the Egyptian National Cancer Institute. He has been honoured with several awards including Scientist of the Year from the International Biographical Centre, Cambridge, UK (2002), the Order of Merit, Cambridge University (2002), the Best Arab Oncologist from the Lebanese Society of Medical Oncology (LSMO,2004) and the recognition award for significant contribution to the Oncology field in the middle east from UAE (Dubai -2013)
Dr Azim was the first to represent the Middle Eastern Region on the ASCO International Affairs Committee from 1997 to 2002. Together with international cancer research leaders, and the French president J. Chiraque, Dr Azim signed the “Charter of Paris against Cancer” on behalf of the Arab World in February 2000. On 2008, Dr. Azim was nominated as the chairman of the steering committee of the NCCN Middle East , which is responsible to set the guide lines of the management of certain cancers in the region. On January 2012 , Dr. Azim was elected to serve as the chairman of the department of clinical oncology ,faculty of medicine,Cairo University
Dr Hendrik-Tobias Arkenau is the founding Medical Director of Sarah Cannon Research Institute UK, and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the Hospital Corporation of America International Cancer Service Line.
Dr Arkenau has vast experience in Early Oncology Clinical Drug Development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. As part of SCRI’s collaboration with University College London (UCL), Dr Arkenau is appointed as a Professorial Research Associate on UCLs faculty and he holds an Honorary Consultant post with UCL Hospitals.
Sarah Cannon Research Institute UK’s remit is to incorporate all aspects of modern drug development from clinical pharmacology, molecular profiling to early clinical trials. The unique operational set-up aims to incorporate oncology drug development into day-to-day clinical practice with the ultimate goal to improve patient care.
Since its inauguration in 2010, Dr Arkenau has built up a trial portfolio of >80 early clinical trials. As Chief- and Principal Investigator he is actively involved in protocol development, toxicity review, pharmacokinetic analysis, biomarker and strategic development of new anti-cancer drugs, including immunotherapies. Dr Arkenau works as part of a multidisciplinary team of more than 40 members comprising of research nurses, operations specialist, project/data manager, regulatory adviser, QA-manager and other oncology specialists.
Dr Arkenau is Fellow of the Royal College of Physicians, and member of The German Cancer Society, ASCO, AACR and ESMO. He has presented multiple talks on the latest research in Oncology and has been Invited Speaker at several national/international meetings. Dr Arkenau has published articles in international peer-reviewed journals (e.g. Lancet, J Clin Oncol, Clin Cancer Res, Annals of Oncologyand others) and serves as ‘Contributing Associate Editor-in-Chief’ of the World Journal of Gastroenterology and ‘Associate Editor’ of World Journal of Cancer Research.
Dr. Faisel Ikram joined City hospital as Consultant General Surgeon / Surgical Gastroenterologist with special interest in advanced laparoscopic surgery.
Graduated from Allama Iqbal Medical College, Punjab University in 1993. Obtained fellowship from the Royal College of Surgeons, Ireland in 1999 and College of Medicine, South Africa in 2003.
After completing his surgical training at Johannesburg General Hospital, he took up a consultant position at the Department of Surgical Gastroenterology and a lecturer at the Wits Medical School, University of Witwatersrand. He completed his sub-speciality training and obtained Certificate of Surgical Gastroenterology in 2006. Thereafter continued to work as a Senior Consultant in his unit specialising in surgical oncology.
He has developed special interest in advanced endoscopic and laparoscopic surgery, mainly colorectal, esophagogastric & pancreatico-biliary surgery. Interventional GI endoscopy, especially ERCP`s & endoluminal stenting are his areas ofspecial interest.
He has been actively involved in conducting training workshops in basic and advanced laparoscopy in South Africa.
Dr Shona Nag completed training in Medical Oncology from Tata Memorial Hospital, Mumbai and St George Hospital, Sydney. She is currently practising in Pune as Senior Oncologist in the Dept of Oncology at Jehangir Hospital and Prime Surgical .Dr Nag has conducted a tumour board at the Sassoon general Hospitals from 2003-2010. She currently is attached as Honorary Oncologist to KEM Hospital Mumbai. Dr Nag is Principal Investigator for over 55 global clinical trials, most of these have been in breast cancer. She has numerous publications and presentations to her credit.
In 2010, Dr Nag was awarded the best principal investigator for clinical research in India by ISCR (a national body). The same year she was also awarded the GSK – Ethnic Research initiative for breast cancer research in developing countries.
She is a member of several International Cancer Societies and ICON (Indian Collaborative Oncology network) and has been on several advisory boards and DSMB’s for drug development in the country.
Her special areas of interest are women cancers. She is also involved in cancer prevention through awareness campaigns and public lectures. Dr Nag is a Trustee of the Nag Foundation, an NGO involved in Cancer care, Research and Education and a co-founder of a support group called BreastFriendsPune which is involved in survivorship aspects of breast cancer care.
Head of Challenge the Experts Session
Professor, Head and Neck Department Tata Memorial Hospital